Hematologic Malignancy
Nodular Lymphocyte Predominant B-Cell Lymphoma
CI-CAN-00001280NLPBL · NLPHLExplore in graph →
Hematologic2 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001280NLPBL · NLPHLExplore in graph →
Clinical trials
16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00107198 | Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease | completed | Phase 2 | 188 | Children's Oncology GroupNETWORK | 6 | Jun 5, 2026 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04858568 | Immune Responses to COVID-19 Vaccination in Lymphoma Patients(PROSECO) | completed | — | 592 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT01026220 | Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma | completed | Phase 3 | 166 | Children's Oncology GroupNETWORK | 5 | Apr 28, 2022 | clinicaltrials |
| NCT01535924 | Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 26 | Beth ChristianOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT02626884 | Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)(IRENO) | completed | Phase 2 | 14 | University of CologneOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT00381940 | Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01460940 | A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00003820 | Rituximab in Treating Patients With Hodgkin's Lymphoma | completed | Phase 2 | 39 | Ranjana AdvaniOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00025259 | Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | completed | Phase 3 | 1,734 | Children's Oncology GroupNETWORK | 7 | Apr 12, 2017 | clinicaltrials |
| NCT01187303 | Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) | completed | Phase 2 | 28 | University of CologneOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00132028 | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jun 5, 2026source: clinicaltrials